Publications

Selected Publications (*equal contribution; # corresponding)

1. Tailoring renal-clearable zwitterionic cyclodextrin for colorectal cancer-selective drug delivery 

M.-J. Baek, D.-T. Nguyen, D. Kim, S.-Y. Yoo, S.M. Lee, J.-Y. Lee, D.-D. Kim, Nature Nanotechnology 18, 945–956 (2023). [IF = 38.1] [Link]

2.  Photobleaching-mediated charge-convertible cyclodextrin nanoparticles achieve deep tumour penetration for rectal cancer theranostics

D.-T. Nguyen*, M.-J. Baek*, S.M. Lee, D. Kim, S.-Y. Yoo, J.-Y. Lee, D.-D. Kim, Nature Nanotechnology 19, 1723–1734 (2024). (*equal contribution) [IF = 38.1] [Link]

3.  Bentonite as a water-insoluble amorphous solid dispersion matrix for enhancing oral bioavailability of poorly water-soluble drugs

M.-J. Baek, J.-H. Park, D.-T. Nguyen, D. Kim, J. Kim, I.-M. Kang, D.-D. Kim, Journal of Controlled Release 363, 525-535 (2023). [IF = 10.5] [Link]

4.  Design considerations for organ-selective nanoparticles

M.-J. Baek*, W. Hur*, S. Kashiwagi, H.S. Choi, ACS Nano, 19, 15, 14605–14626 (2025) (*equal contribution) [IF = 15.8] [Link]

5.  Breakthroughs in Deep Tumor Penetrating Nano-Phototheranostics for Tumor ablation

M.-J. Baek*, S.M. Lee*, D.-D. Kim, J.-Y. Lee, Clinical and Translational Medicine 15, 370188 (2025) (*equal contribution) [IF = 7.9] [Link]

Journal Articles (*equal contribution; # corresponding)

2025

18. M.-J. Baek*, W. Hur*, S. Kashiwagi, H.S. Choi, Design considerations for organ-selective nanoparticles, ACS Nano, 19, 15, 14605–14626 (2025).

17. M.-J. Baek*, S.M. Lee*, D.-D. Kim, J.-Y. Lee, Breakthroughs in Deep Tumor Penetrating Nano-Phototheranostics for Tumor ablation, Clinical and Translational Medicine 15, 370188 (2025). 

2024

16. D.-T. Nguyen*, M.-J. Baek*, S.M. Lee, D. Kim, S.-Y. Yoo, J.-Y. Lee, D.-D. Kim, Photobleaching-mediated charge-convertible cyclodextrin nanoparticles achieve deep tumour penetration for rectal cancer theranostics, Nature Nanotechnology 19, 1723–1734 (2024). 

• Featured in “News and Views” in Nature Nanotechnology (21 August 2024): A photo-controlled charge regulator improves cancer theranostics.

15. S. Hwang, B.E. Heo, T.Q. Nguyen, Y.J. Kim, S.-G. Lee, T.-H. Huynh, E. Kim, S.-I. Jo, M.-J. Baek, E.-K. Shin, J. Oh, Y.J. Yoon, E.-J. Park, K.T. Kim, S. Ryoo, D.-G. Lee, C. Wood, M. Woo, D.-D. Kim, S. Paik, E.-K. Jo, J. Jang, D.-C. Oh, “Arenicolide Family Macrolides Provide a New Therapeutic Lead Combating Multidrug-Resistant Tuberculosis”, Angewandte Chemie International Edition 64, 1, e202412994 (2024). 

14. S.-Y. Yoo, H.Y. Kim, D.H. Kim, W.S. Shim, S.M. Lee, D.H. Lee, J.M. Koo, J.H. Yoo, S. Koh, J.C. Park, J. Yu, J.S. Jeon, M.-J. Baek, D.-D. Kim, J.-Y. Lee, S.J. Oh, S.K. Kim, J.-Y. Lee, K.W. Kang, Laser-Responsive Erastin-Loaded Chondroitin Sulfate Nanomedicine Targeting CD44 and System xc− in Liver Cancer: A Non-Ferroptotic Approach, Journal of Controlled Release 375, 574-588 (2024). 

13. D.-T. Nguyen, M.-H. Kim, M.-J. Baek, N.-W. Kang, D.-D. Kim, Preparation and evaluation of proliposomes formulation for enhancing the oral bioavailability of ginsenosides, Journal of Ginseng Research 48, 4, 417-424 (2024). 

12. T.-K. Kim, J.-E. Lee, K. Jeong, M.-J. Baek, D. Kim, J.-Y. Jeong, S. Lee D.-D. Kim, Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension and dyslipidemia, Journal of Pharmaceutical Investigation 54, 99–112 (2024). 

11. T.-K. Kim, F. Fina, F. Rossignolo, S.-H. Kim, H. Lee, K. Jeong, X. Xu; C. Pignaffo, C. Yang; J. Koo, M. Lee, M.-J. Baek, D. Kim, D.-D. Kim, Evaluation of a spray-dried amorphous solid dispersion formulation of ID11916, a new molecular entity with dual inhibition mechanisms targeting the androgen receptor and phosphodiesterase type-5, Journal of Pharmaceutical Investigation 54, 317-327 (2024). 

2023

10. M.-J. Baek, D.-T. Nguyen, D. Kim, S.-Y. Yoo, S.M. Lee, J.-Y. Lee, D.-D. Kim, Tailoring renal-clearable zwitterionic cyclodextrin for colorectal cancer-selective drug delivery, Nature Nanotechnology 18, 945–956 (2023). 

9. M.-J. Baek, J.-H. Park, D.-T. Nguyen, D. Kim, J. Kim, I.-M. Kang, D.-D. Kim, Bentonite as a water-insoluble amorphous solid dispersion matrix for enhancing oral bioavailability of poorly water-soluble drugs, Journal of Controlled Release 363, 525-535 (2023). 

• [Inside Front Cover] 

2022

8. M.-J. Baek, H.-J. Shin, J.-H. Park, J. Kim, I.-M. Kang, J.I. Lee, D.-D. Kim, Preparation and evaluation of the doxazosin-bentonite composite as a pH-dependent controlled-release oral formulation, Applied Clay Science 229. 106677 (2022). 

7. M.-J. Baek*, G.-H. Kim*, J.-H. Park, J. Kim, I.-M. Kang, J.I. Lee, D.-D. Kim, Effect of phosphatidylcholine in bentonite-quetiapine complex on enhancing drug release and oral bioavailability, International Journal of Pharmaceutics 628, 122347 (2022). 

6. D.-T. Nguyen, M.-H. Kim, N.-Y. Yu, M.-J. Baek, K.-S. Kang, K.W. Lee, D.-D. Kim, Combined Orobol-Bentonite Composite Formulation for Effective Topical Skin Targeted Therapy in Mouse Model, International Journal of Nanomedicine 17, 6513-6525 (2022). 

2019-2021

5. J.-H. Park, M.-J. Baek, J.-Y. Lee, K.-T. Kim, H-J. Cho, D.-D. Kim, Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability, International Journal of Pharmaceutics 589, 119836 (2020). 

4. S.Y. Lee, J.-H. Park, M. Yang, M.-J. Baek, M.-H. Kim, J. Lee, A. Khademhosseini, D.-D. Kim, H.-J. Cho, Ferrous sulfate-directed dual-cross-linked hyaluronic acid hydrogels with long-term delivery of donepezil, International Journal of Pharmaceutics 582, 119309 (2020). 

3. M.-H. Kim, D.H. Kim, D.-T. Nguyen, H.S. Lee, N.-W. Kang, M.-J. Baek, J. An, S.-Y. Yoo, Y.-H. Mun, W. Lee, K-T. Kim, C.-W. Cho, J.-Y. Lee, D.-D. Kim, Preparation and Evaluation of Eudragit L100-PEG Proliponiosomes for Enhanced Oral Delivery of Celecoxib, Pharmaceutics 12, 718 (2020). 

2. S.Y. Jung, J.-H. Park, M.-J. Baek, G.-H. Kim, J. Kim, H.-M. Zheng, J.-M. Kim, I.-M. Kang, D.-D. Kim, J.I. Lee, Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis, International Journal of Pharmaceutics 578, 119103 (2020). 

1. D. Jeon, K.-T. Kim, M.-J. Baek, D.H. Kim, J.-Y. Lee, D.-D. Kim, Preparation and evaluation of celecoxib-loaded proliposomes with high lipid content, European Journal of Pharmaceutics and Biopharmaceutics 141, 139-148 (2019).

Patents

10. Liposome-bentonite complex with improved oral bioavailability of drug, and preparing method thereof. Application in KOREA (2024), Application number: 10-2024-0171937.

9. Charge-convertible nanoparticle, and medical use thereof. Application in KOREA (2023), Application number: 10-2023-0152794.

8. Drug-clay mineral complex containing phospholipid and oral administration composition including same. US Patent App. (2023), 18/013, 919.

7. Composition comprising clay mineral complex for prevention, alleviation, and treatment of inflammatory bowel disease, preparation method for composition, and method for inflammatory bowel disease. US Patent App. (2022), 17/603, 093.

6. Controlled-release composition for oral administration comprising complex of alpha-adrenergic blocker compound and clay mineral. US Patent App. (2022), 17/620, 577.

5. Composition for oral administration with controlled release properties comprising complex of clay minerals, method for preparing same, and method for controlling release properties. US Patent App. (2022), 17/603, 094.

4. A clay mineral-drug complex with phospholipid and an oral administration composition including the same. Registration in KOREA (2021), Registration number: 10-2212402.

3. A controlled-release composition comprising a clay mineral complex for oral administration, Registration in KOREA (2019), Registration number: 10-2035479.

2. A composition for prevention, improvement and treatment of inflammatory bowel disease comprising a clay mineral complex. Registration in KOREA (2019), Registration number: 10-2035481.

1.  A controlled-release composition comprising a complex of a clay mineral and alpha-adrenergic blocking agent for administration. Registration in KOREA (2019), Registration number: 10-2054346.